
Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Adaptimmune Therapeutics PLC?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.197
1.39
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does Adaptimmune Therapeutics PLC hold over its rivals?
What risks and challenges
does Adaptimmune Therapeutics PLC face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Adaptimmune Therapeutics PLC.
Provide an overview of the primary business activities
of Adaptimmune Therapeutics PLC.
What unique competitive advantages
does Adaptimmune Therapeutics PLC hold over its rivals?
What risks and challenges
does Adaptimmune Therapeutics PLC face in the near future?
Summarize the latest earnings call
of Adaptimmune Therapeutics PLC.
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Adaptimmune Therapeutics PLC.
Provide P/S
for Adaptimmune Therapeutics PLC.
Provide P/E
for Adaptimmune Therapeutics PLC.
Provide P/OCF
for Adaptimmune Therapeutics PLC.
Provide P/FCFE
for Adaptimmune Therapeutics PLC.
Provide P/B
for Adaptimmune Therapeutics PLC.
Provide EV/S
for Adaptimmune Therapeutics PLC.
Provide EV/GP
for Adaptimmune Therapeutics PLC.
Provide EV/EBITDA
for Adaptimmune Therapeutics PLC.
Provide EV/EBIT
for Adaptimmune Therapeutics PLC.
Provide EV/OCF
for Adaptimmune Therapeutics PLC.
Provide EV/FCFF
for Adaptimmune Therapeutics PLC.
Provide EV/IC
for Adaptimmune Therapeutics PLC.
Show me price targets
for Adaptimmune Therapeutics PLC made by professional analysts.
What are the Revenue projections
for Adaptimmune Therapeutics PLC?
How accurate were the past Revenue estimates
for Adaptimmune Therapeutics PLC?
What are the Net Income projections
for Adaptimmune Therapeutics PLC?
How accurate were the past Net Income estimates
for Adaptimmune Therapeutics PLC?
What are the EPS projections
for Adaptimmune Therapeutics PLC?
How accurate were the past EPS estimates
for Adaptimmune Therapeutics PLC?
What are the EBIT projections
for Adaptimmune Therapeutics PLC?
How accurate were the past EBIT estimates
for Adaptimmune Therapeutics PLC?
Compare the revenue forecasts
for Adaptimmune Therapeutics PLC with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Adaptimmune Therapeutics PLC and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Adaptimmune Therapeutics PLC against its competitors.
Analyze the profit margins
(gross, operating, and net) of Adaptimmune Therapeutics PLC compared to its peers.
Compare the P/E ratios
of Adaptimmune Therapeutics PLC against its peers.
Discuss the investment returns and shareholder value creation
comparing Adaptimmune Therapeutics PLC with its peers.
Analyze the financial leverage
of Adaptimmune Therapeutics PLC compared to its main competitors.
Show all profitability ratios
for Adaptimmune Therapeutics PLC.
Provide ROE
for Adaptimmune Therapeutics PLC.
Provide ROA
for Adaptimmune Therapeutics PLC.
Provide ROIC
for Adaptimmune Therapeutics PLC.
Provide ROCE
for Adaptimmune Therapeutics PLC.
Provide Gross Margin
for Adaptimmune Therapeutics PLC.
Provide Operating Margin
for Adaptimmune Therapeutics PLC.
Provide Net Margin
for Adaptimmune Therapeutics PLC.
Provide FCF Margin
for Adaptimmune Therapeutics PLC.
Show all solvency ratios
for Adaptimmune Therapeutics PLC.
Provide D/E Ratio
for Adaptimmune Therapeutics PLC.
Provide D/A Ratio
for Adaptimmune Therapeutics PLC.
Provide Interest Coverage Ratio
for Adaptimmune Therapeutics PLC.
Provide Altman Z-Score Ratio
for Adaptimmune Therapeutics PLC.
Provide Quick Ratio
for Adaptimmune Therapeutics PLC.
Provide Current Ratio
for Adaptimmune Therapeutics PLC.
Provide Cash Ratio
for Adaptimmune Therapeutics PLC.
What is the historical Revenue growth
over the last 5 years for Adaptimmune Therapeutics PLC?
What is the historical Net Income growth
over the last 5 years for Adaptimmune Therapeutics PLC?
What is the current Free Cash Flow
of Adaptimmune Therapeutics PLC?
Discuss the annual earnings per share (EPS)
trend over the past five years for Adaptimmune Therapeutics PLC.
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
UK |
![]() |
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
91.9m USD | -1.6 | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 789.6 |
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
336.1B USD | 15.4 |
|
US |
![]() |
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD | -13 213.5 |
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
164.8B USD | 14.8 |
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
144.7B USD | 10.5 |
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.7B USD | 26 |
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -580 |
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
129.7B AUD | 19 |
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.9B USD | 12.1 |
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.5 |
|
EBITDA Growth | EV/EBITDA to Growth | |||||
---|---|---|---|---|---|---|
UK |
![]() |
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Average EV/EBITDA:
16.3
|
N/A | N/A | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
Negative Multiple: -194 789.6 | N/A | N/A |
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
15.4
|
13%
|
1.2 |
|
US |
![]() |
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
Negative Multiple: -13 213.5 | N/A | N/A |
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
14.8
|
17%
|
0.9 |
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
10.5
|
6%
|
1.8 |
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
26
|
17%
|
1.5 |
|
US |
E
|
Epizyme Inc
F:EPE
|
Negative Multiple: -580 | N/A | N/A |
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
19
|
11%
|
1.7 |
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
12.1
|
11%
|
1.1 |
|
US |
S
|
Seagen Inc
F:SGT
|
Negative Multiple: -66.5 | N/A | N/A |
|
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.